Bristol-Myers Squibb to Buy Amylin for $7 Billion
Also Bristol-Myers Squibb and AstraZeneca, announced that, following the acquisition of Amylin, the companies will enter into collaboration arrangements regarding the development and commercialization of Amylin's portfolio of products.